You just read:

Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis

News provided by

Sun Pharmaceutical Industries Ltd.

Jun 14, 2019, 02:07 ET